慢性阻塞性肺疾病全球倡议（GOLD）分类及指南的影响
Implications of the GOLD COPD Classification and Guidelines.
作者信息
Martinez Carlos H, Curtis Jeffrey L
机构信息
and are affiliated with Pulmonary & Critical Care Medicine Section, Medicine Service, VA Ann Arbor Healthcare System, Ann Arbor, Michigan and Pulmonary & Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor.
出版信息
Fed Pract. 2015 Sep;32(Suppl 10):14S-18S.
Abstract
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines classification is based on the combination of patient risk and the severity of their symptoms.
摘要
慢性阻塞性肺疾病全球倡议（GOLD）指南分类基于患者风险及其症状严重程度的综合情况。
相似文献
1
Implications of the GOLD COPD Classification and Guidelines.慢性阻塞性肺疾病全球倡议（GOLD）分类及指南的影响
Fed Pract. 2015 Sep;32(Suppl 10):14S-18S.
2
Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study.应用 2017 年新版全球慢性阻塞性肺疾病倡议分类标准预测慢性阻塞性肺疾病患者的死亡率：一项队列研究。
Lancet Respir Med. 2018 Mar;6(3):204-212. doi: 10.1016/S2213-2600(18)30002-X. Epub 2018 Jan 10.
3
The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study.2011年和2017年慢性阻塞性肺疾病全球倡议（GOLD）指南对台湾慢性阻塞性肺疾病患者分配及药物治疗的影响：台湾阻塞性肺病（TOLD）研究
Int J Chron Obstruct Pulmon Dis. 2018 Sep 25;13:2949-2959. doi: 10.2147/COPD.S176065. eCollection 2018.
4
Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease.澳大利亚与国际慢性阻塞性肺疾病严重程度分级指南的比较
Intern Med J. 2006 Aug;36(8):506-12. doi: 10.1111/j.1445-5994.2006.01142.x.
5
Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis.药物治疗依从性的差异与慢性阻塞性肺疾病全球倡议（GOLD）：回顾性 actuarial 理赔数据分析。
Curr Med Res Opin. 2011 Jul;27(7):1425-9. doi: 10.1185/03007995.2011.583230. Epub 2011 May 23.
6
The adherence to and utility of the Global Initiative for Chronic Obstructive Lung Disease guidelines for treating COPD among pulmonary specialists: a retrospective analysis.肺科专家对慢性阻塞性肺疾病全球倡议指南治疗 COPD 的依从性和实用性：回顾性分析。
BMC Pulm Med. 2023 Jun 19;23(1):216. doi: 10.1186/s12890-023-02503-7.
7
Classification of patients with chronic obstructive pulmonary disease according to the Latin American Thoracic Association (ALAT) staging systems and the global initiative for chronic obstructive pulmonary disease (GOLD).根据拉丁美洲胸科学会（ALAT）分期系统和全球慢性阻塞性肺疾病倡议（GOLD）对慢性阻塞性肺疾病患者进行分类。
Arch Bronconeumol. 2017 Mar;53(3):98-106. doi: 10.1016/j.arbres.2016.08.015. Epub 2016 Dec 10.
8
Six-minute-walk distance and accelerometry predict outcomes in chronic obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group.六分钟步行距离和加速度计可独立于慢性阻塞性肺疾病全球倡议组织2011年分组预测慢性阻塞性肺疾病的预后。
Ann Am Thorac Soc. 2015 Mar;12(3):349-56. doi: 10.1513/AnnalsATS.201408-365OC.
9
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines Reviewed.《慢性阻塞性肺疾病全球倡议（GOLD）2023年指南》述评
Open Respir Med J. 2024 Jan 10;18:e18743064279064. doi: 10.2174/0118743064279064231227070344. eCollection 2024.
10
Costs of pharmacotherapy of chronic obstructive pulmonary disease in relation to changing Global Initiative for Chronic Obstructive Lung Disease guidelines (2007, 2011, and 2017 updates).慢性阻塞性肺疾病药物治疗的成本与全球慢性阻塞性肺疾病倡议指南的变化有关（2007、2011 和 2017 年更新）。
Pol Arch Intern Med. 2019 May 31;129(5):308-315. doi: 10.20452/pamw.4487. Epub 2019 Mar 14.
引用本文的文献
1
Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病中基于表型到可治疗特征的管理
Cureus. 2024 May 16;16(5):e60423. doi: 10.7759/cureus.60423. eCollection 2024 May.
2
Adjusting perioperative methadone dose for elderly and fragile hip fracture patients (MetaHip-trial) - A statistical analysis plan for an adaptive dose-finding trial.调整老年及脆弱髋部骨折患者围手术期美沙酮剂量（MetaHip试验）——一项适应性剂量探索试验的统计分析计划
Contemp Clin Trials Commun. 2023 Nov 14;36:101228. doi: 10.1016/j.conctc.2023.101228. eCollection 2023 Dec.
3
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19.癌症患者在化疗或免疫治疗期间感染 COVID-19 的死亡率。
JAMA Netw Open. 2022 Feb 1;5(2):e220130. doi: 10.1001/jamanetworkopen.2022.0130.
本文引用的文献
1
Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial.2013年慢性阻塞性肺疾病全球倡议（GOLD）分级能否提高预测肺功能下降、急性加重和死亡率的能力：对为期4年的UPLIFT试验的事后分析
BMC Pulm Med. 2014 Oct 18;14:163. doi: 10.1186/1471-2466-14-163.
2
Factors predictive of airflow obstruction among veterans with presumed empirical diagnosis and treatment of COPD.在接受慢性阻塞性肺疾病（COPD）经验性诊断和治疗的退伍军人中，气流阻塞的预测因素。
Chest. 2015 Feb;147(2):369-376. doi: 10.1378/chest.14-0672.
3
The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients.慢性阻塞性肺疾病评估测试（CAT）有助于预测高危患者的慢性阻塞性肺疾病急性加重情况。
Respir Med. 2014 Apr;108(4):600-8. doi: 10.1016/j.rmed.2013.12.014. Epub 2014 Jan 6.
4
Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A cross-sectional study.与慢性阻塞性肺疾病全球倡议（GOLD）1234分级相比，GOLD ABCD组与健康状况及费用的关联是否更紧密？一项横断面研究。
Prim Care Respir J. 2014 Mar;23(1):30-7. doi: 10.4104/pcrj.2014.00002.
5
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.COPDGene 研究中的 GOLD 2011 疾病严重程度分类：一项前瞻性队列研究。
Lancet Respir Med. 2013 Mar;1(1):43-50. doi: 10.1016/S2213-2600(12)70044-9. Epub 2012 Sep 3.
6
The distribution of COPD in UK general practice using the new GOLD classification.使用新的 GOLD 分类法在英国普通实践中 COPD 的分布。
Eur Respir J. 2014 Apr;43(4):993-1002. doi: 10.1183/09031936.00065013. Epub 2013 Oct 31.
7
Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.联合使用皮质类固醇和长效β2受体激动剂的单一吸入器与单独使用吸入性皮质类固醇治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2013 Aug 30;2013(8):CD006826. doi: 10.1002/14651858.CD006826.pub2.
8
Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease.慢性阻塞性肺疾病频繁加重表型的机制和影响。
BMC Med. 2013 Aug 14;11:181. doi: 10.1186/1741-7015-11-181.
9
Guideline adherence in management of stable chronic obstructive pulmonary disease.稳定期慢性阻塞性肺疾病管理中的指南依从性。
Respir Med. 2013 Jul;107(7):1046-52. doi: 10.1016/j.rmed.2013.04.001. Epub 2013 Apr 30.
10
Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization.2011 年和 2007 年全球慢性阻塞性肺疾病倡议指南预测死亡率和住院率的比较。
Am J Respir Crit Care Med. 2013 Jul 1;188(1):51-9. doi: 10.1164/rccm.201212-2276OC.
Zotero 插件